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Abstract 
Background. The single-arm, phase II Tasigna Efficacy in Advanced Melanoma 
(TEAM) trial evaluated the KIT-selective tyrosine kinase inhibitor nilotinib in patients with 
KIT-mutated advanced melanoma without prior KIT inhibitor treatment. 
Patients and Methods. Forty-two patients with KIT-mutated advanced melanoma were 
enrolled and treated with nilotinib 400 mg twice daily. TEAM originally included a 
comparator arm of dacarbazine (DTIC)-treated patients; the design was amended to a 
single-arm trial due to an observed low number of KIT-mutated melanomas. Thirteen 
patients were randomized to DTIC prior to the protocol amendment removing this study 
arm. The primary endpoint was objective response rate (ORR), determined according to 
Response Evaluation Criteria In Solid Tumors. 
Results. ORR was 26.2% (n=11/42; 95% CI, 13.9%-42.0%), sufficient to reject the null 
hypothesis (ORR ≤10%). All observed responses were partial responses (PRs; median 
response duration, 7.1 months). Twenty patients (47.6%) had stable disease, 10 
(23.8%) had progressive disease, and 1 (2.4%) response was unknown. Ten of the 11 
responding patients had exon 11 mutations, 4 with an L576P mutation. The median 
progression-free survival and overall survival were 4.2 months and 18.0 months, 
respectively. Three of 13 patients on DTIC achieved a PR, and another patient had a 
PR following switch to nilotinib. 
Conclusion. Nilotinib activity in patients with advanced KIT-mutated melanoma was 
similar to historical data from imatinib-treated patients. DTIC treatment showed potential 
activity, although the low patient number limits interpretation. Similar to previously 
reported results with imatinib, nilotinib showed greater activity among patients with an 
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exon 11 mutation, including L576P, suggesting that nilotinib may be an effective 
treatment option for patients with specific KIT mutations. 
 
Clinical Trial Registration: ClinicalTrials.gov, NCT01028222 
 
Keywords: KIT, melanoma, tyrosine kinase inhibitor, nilotinib, dacarbazine, imatinib 
 
Key Message: 
In a phase II, single-arm trial, the KIT-selective tyrosine kinase inhibitor nilotinib 
demonstrated activity in patients with KIT-mutated advanced melanoma. The activity of 
nilotinib was similar to historical data from imatinib-treated patients, suggesting that 
nilotinib may be an effective treatment option for patients with KIT-mutated melanoma. 
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Introduction 
Mutations in the stem cell factor receptor tyrosine kinase gene (KIT) are observed in 
≈2% of all melanomas [1], often leading to upregulated signaling from the corresponding 
protein KIT. KIT mutations are most common in acral and mucosal melanomas and less 
often observed in cutaneous melanoma arising from skin with chronic sun damage 
(CSD) [2]. KIT mutations are widely distributed over the coding region and observed in 
exons 9, 11, 13, 17, and 18 [2, 3]. Advanced melanomas with KIT aberrations 
(mutations and/or amplifications) have been shown to respond to the BCR-ABL1/KIT 
tyrosine kinase inhibitor (TKI) imatinib (Gleevec, Novartis Pharmaceuticals Corporation) 
[4-9], although response rates are low compared with BRAF inhibitors in BRAF-mutated 
melanomas [10, 11]. Nilotinib (Tasigna, Novartis Pharmaceuticals Corporation) has also 
demonstrated activity against several known KIT mutations in vitro, with potency 
comparable to or greater than that of imatinib (Table S1) [12, 13], and is less likely to 
lead to gastrointestinal or fluid retention–related adverse events (AEs) [14]. Nilotinib has 
thus been investigated as a potential treatment for KIT-mutated melanomas [15-18]. A 
phase II study in patients with advanced KIT-mutated melanoma reported partial 
responses (PRs) in 3 of 19 nilotinib-treated patients (15.8%), including 2 with prior 
imatinib resistance. The Tasigna Efficacy in Advanced Melanoma (TEAM; 
ClinicalTrials.gov, NCT01028222) trial was the first open-label, multicenter, single-arm, 
phase II study to assess the efficacy and safety of nilotinib in patients with KIT-mutated 
advanced melanoma without prior KIT inhibitor therapy. 
 
6 
 
Methods 
Patients, Study Design, and Treatment 
Patients were enrolled at 29 centers in 11 countries (Australia, Belgium, Brazil, Canada, 
China, Germany, Italy, Spain, Sweden, Switzerland, and the United States). Eligible 
patients were adults with histologically confirmed unresectable or metastatic acral, 
mucosal, or CSD melanoma without a history of brain metastases and with a confirmed 
KIT mutation in exons 9, 11, 13, or 17 (D820G, N822H, N822K, D820Y, Y822D, or 
Y823D), which have known KIT inhibitor sensitivity [4-6, 13]. Following a protocol 
amendment, patients with CSD melanoma were excluded from further enrollment 
because of a low observed KIT mutation rate. Mutation status was determined in a 
central laboratory (MolecularMD, Portland, OR) by DNA extraction from formalin-fixed, 
paraffin-embedded tumor tissue that was macrodissected, followed by polymerase 
chain reaction amplification and sequencing using a panel of direct sequencing assays 
with 20% mutant allele sensitivity. Germline DNA was not sequenced to determine if 
mutations were somatic. 
 
Patients with KIT amplification without mutation were ineligible. Additional exclusion 
criteria included prior treatment with any TKI or >1 systemic anticancer therapy for 
melanoma in addition to any adjuvant therapy. Patients with significantly impaired 
cardiac function were ineligible, as were those with gastrointestinal impairment, chronic 
or acute pancreatitis, and/or acute or chronic liver or renal disease unrelated to 
melanoma. 
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Originally, the TEAM trial was a randomized, phase III study of nilotinib vs dacarbazine 
(DTIC; standard of care), with a target enrollment of 120 patients. This was amended to 
an open-label, single-arm design due to the rarity of patients harboring KIT mutations. 
Although 13 patients were randomized to DTIC prior to the protocol amendment and 10 
eventually switched to nilotinib, the focus of this analysis is on the patients whose initial 
treatment was nilotinib. All patients assigned to nilotinib received nilotinib 400 mg twice 
daily. Dose adjustments were allowed per protocol-specified criteria (Supplementary 
Methods). 
 
Study Endpoints and Assessments 
The primary endpoint was the objective response rate (ORR), defined as the proportion 
of patients with a confirmed complete response (CR) or PR determined by the 
investigator according to Response Evaluation Criteria In Solid Tumors (RECIST). 
Tumor progression was assessed by computed tomography/magnetic resonance 
imaging or photography at screening, baseline, weeks 3, 6, 9, 12, 18, and 24, and every 
12 weeks thereafter. 
 
Key secondary endpoints included Kaplan-Meier (KM) estimates of progression-free 
survival (PFS; time from treatment start to date of first documented progression or 
death) and overall survival (OS; time from study start to date of death from any cause; 
Supplementary Methods). Additional secondary endpoints included KM-estimated 
duration of objective response (DOR; time from first documented CR or PR to first 
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documented progression or death) and disease control rate (DCR; proportion of patients 
with CR, PR, or stable disease [SD] for ≥12 weeks from start of treatment). 
 
AEs were assessed according to the Common Terminology Criteria for Adverse Events 
(CTCAE) version 3.0. Safety was evaluated on an ongoing basis during study treatment 
and ≤30 days after the last dose of study treatment. 
 
Statistical Analyses 
Demographics, baseline characteristics, and efficacy analyses were determined in the 
intent-to-treat population, including all patients assigned to nilotinib. Patients 
randomized to DTIC prior to the study design amendment were analyzed separately. 
Demographics and baseline characteristics were summarized by descriptive statistics. 
Safety analyses were determined in the safety population, including all patients who 
received ≥1 dose of study medication. 
 
For the primary endpoint, the null hypothesis (ORR ≤10%) was tested according to 
Simon’s 2-stage design. After all 23 nilotinib-treated patients enrolled in the first stage 
had a confirmed response, discontinued the study, or completed 24 weeks of treatment, 
the trial was to be discontinued (null hypothesis accepted) if <3 confirmed responses 
were observed. If ≥3 confirmed responses were observed, the second stage would 
begin with an enrollment target of an additional 18 patients. If there were ≥9 responders 
overall, the null hypothesis would be rejected with a 1-sided significance level of 2.5% 
and a power of 90% against an alternative hypothesis of ORR ≥30%. 
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Ethics 
This study was conducted in accordance with the ethical principles of the Declaration of 
Helsinki and local laws/regulations. Patients provided written informed consent prior to 
participation. The study protocol and all amendments were reviewed and approved by 
an institutional review board or independent ethics committee for each center. 
 
Results 
Patients and Treatment Exposure 
Between 29 April 2010 and 23 October 2012, 877 patients were prescreened for KIT 
mutations. While a mutation frequency of 20%-30% was expected in the target 
population based on prestudy estimates [2], only 106 (12.1%) prescreened patients 
harbored KIT mutations (Figure S1). Of these, 78 were screened for eligibility per 
additional inclusion/exclusion criteria, and 55 enrolled. Primary reasons for screening 
failure were unacceptable laboratory or test procedure results (eg, brain metastasis). 
Prior to closure of the DTIC arm (via protocol amendment 27 July 2011), 14 and 13 
patients were randomized to nilotinib and DTIC, respectively. Ten patients on DTIC 
subsequently crossed over to nilotinib; the remaining 3 discontinued (loss to follow-up, 
disease progression, administrative problems [n=1 each]). Herein, demographic, 
efficacy, and safety data are reported for patients who initiated nilotinib treatment upon 
enrollment (N=42), with brief mention of the DTIC results. Further details regarding 
efficacy/safety for patients randomized to DTIC are included in the Appendix. 
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In the nilotinib arm, acral and mucosal melanomas were most frequent (n=20; 47.6% 
each; information on primary site is in Table 1); 2 patients (4.8%) had CSD melanoma 
of the head and neck (patients with CSD melanoma were excluded from the study 
following a protocol amendment). The most frequently observed KIT mutations were in 
exon 11 (n=26; 61.9%; most commonly L576P [n=10]) and exon 13 (n=13; 31.0%). 
 
By study completion (last patient last visit, 31 December 2014), 38 patients (90.5%) had 
discontinued nilotinib, most commonly for disease progression (n=33; 86.8%). Known 
subsequent treatments following study discontinuation included chemotherapy/radiation 
(n=18), ipilimumab (n=15), imatinib (n=8), and other targeted/immune therapies (n=7). 
Four patients (9.5%) remained on nilotinib through a rollover study or local protocol. 
Median duration of nilotinib exposure was 15.0 weeks (range, 1-154 weeks). Dose 
interruptions due to AEs were reported in 26 patients (61.9%). Twenty-two patients 
(52.4%) received a reduced dose, with 6 patients having ≥1 direct dose reduction to 400 
mg once daily without prior interruption. The lowest nilotinib dose received was 400 mg 
daily in 21 patients and 200 mg daily in 1 patient. The median percentage of days on 
study that patients received a full nilotinib dose was 75.5% (range, 12%-98%). 
 
Efficacy 
Among the 42 patients in the nilotinib arm, the ORR was 26.2% (95% CI, 13.9%-42.0%; 
PR, n=11; CR, n=0), sufficient to reject the null hypothesis of ORR ≤10% (Table 2). All 
responses occurred by 3 months; 5 occurred by 3 weeks and 7 by 6 weeks. Median 
DOR was 7.1 months (range, 2.8-34.6 months). Twenty patients (47.6%) had SD ≥6 
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weeks, 10 (23.8%) had progressive disease, and 1 (2.4%) response was unknown. The 
DCR was 47.6%. Three of 13 patients in the DTIC arm had a PR (ORR, 23.1%; CR, 
n=0; PR, n=3; Tables S2 and S3). 
 
Response rate differed by mutation status; PR was observed in 10 of 26 patients 
(38.5%) with an exon 11 mutation, 1 of 13 patients (7.7%) with an exon 13 mutation, 
and 0 of 3 patients with an exon 9 or 17 mutation (Figure 1A). Of the 10 responding 
patients with an exon 11 mutation, 3 had the L576P mutation and 1 had a combined 
L576P/W557R mutation (Table 3). While the majority of observed mutations affect 
recurrently mutated sites and are thus considered likely to lead to constitutive KIT 
activation, a few of the identified mutations (ie, S476C and D496N in exon 9 and 
R634W in exon 13) affect nonrecurrent sites and therefore may not be pathogenic. 
 
Thirty-five patients had PFS events (median PFS of 4.2 months; 95% CI, 2.1-5.8 
months). At 6 months, the estimated PFS rate was 34.6% (95% CI, 20.2%-49.3%; 
Figure 1B). Among the 26 patients with an exon 11 mutation, median PFS was 5.4 
months (95% CI, 2.7-8.3 months); the 6-month estimated PFS rate was 43.1% (95% CI, 
23.4%-61.5%). 
 
Twenty-six deaths occurred (due to melanoma [n=24], cardiopulmonary arrest [n=1], 
multiorgan dysfunction [n=1]). Of these, 1 death (due to melanoma) occurred within 30 
days of discontinuation. No deaths were considered by the investigators to be 
attributable to nilotinib. Median OS was 18.0 months (95% CI, 10.9-20.3 months). 
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Estimated OS rates at 12 and 24 months were 63.6% (95% CI, 46.4%-76.6%) and 
27.7% (95% CI, 13.3%-44.2%), respectively (Figure 1C). Among the 26 patients with 
an exon 11 mutation, 17 died on study and 3 were alive and receiving nilotinib with 
≥25.8 months’ follow-up. PFS and OS in DTIC-treated patients are shown in Figure S2. 
 
Safety 
Nilotinib was well tolerated, with a safety profile consistent with reports of nilotinib in 
patients with chronic myeloid leukemia [14]. No additional safety issues were observed 
on crossover to nilotinib, although data for this population are limited. Full safety data 
are provided in Tables S4, S5, and S6. 
 
Discussion 
Results from the TEAM trial showed that nilotinib is an active agent in patients with KIT-
mutated metastatic melanoma. Similar results have been reported in other studies of 
nilotinib in patients with advanced melanoma with KIT aberrations, including patients 
with prior imatinib resistance [15-17]; response rates and survival in these nilotinib 
studies are similar to those in reports of imatinib treatment in patients with KIT-mutated 
melanoma (Table S7) [7-9]. 
 
Response rates to imatinib and nilotinib in patients with KIT mutations [7-9, 15-17] are 
approximately half of those observed in pivotal trials of BRAF inhibitors in patients with 
BRAF-mutated advanced melanoma [10, 11]. This may result from heterogeneity of KIT 
mutations relative to BRAF mutations (of which 74% are V600E) and/or a lower efficacy 
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of current KIT inhibitors [19]. Additionally, RAS mutations may confer resistance to KIT 
inhibitors [9]; although prior data suggest low incidences of concurrent KIT/RAS 
mutations [2, 9], the RAS mutation status of patients enrolled in TEAM is unknown. 
 
Although the TEAM trial was not powered to statistically determine response rates 
according to mutation subtypes, numerical differences were observed by mutation. 
Patients with an exon 11 mutation had a better response rate than patients with an exon 
13 mutation. Too few patients had exon 9 or 17 mutations to draw conclusions in these 
subpopulations. Consistent with prior studies of imatinib and nilotinib, the most 
frequently observed mutation among responding patients in TEAM was L576P on exon 
11 [9, 16], a common KIT-activating mutation [2, 20]. Results from TEAM suggest that 
nilotinib may have activity in these patients, with 4 of 10 patients (40.0%) with L576P 
(including 1 with a concurrent W557R mutation) responding to nilotinib. 
 
The response rate among DTIC-treated patients (23.1%) was higher than has been 
historically observed for DTIC [21], suggesting that patients enrolled in TEAM may have 
had less aggressive disease than the general population of patients with advanced KIT-
mutated melanomas. Formal comparison of nilotinib and DTIC was not conducted due 
to partial randomization in the nilotinib arm and the very low number of patients in the 
DTIC arm. A randomized controlled trial of nilotinib vs standard of care in patients with 
advanced KIT-mutated melanoma may be needed to further evaluate nilotinib efficacy in 
this population. However, the inability to recruit a sufficient number of patients for a 
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randomized controlled trial demonstrates the difficulty of conducting large trials in 
uncommon molecular subsets of advanced diseases. 
 
Potential limitations of this study include the lower enrollment target and changes in 
study design following the protocol amendments, which may have impacted the strength 
of the results. Additionally, the majority of patients had mucosal/acral melanoma, 
potentially limiting the generalizability of the findings to other subtypes known to harbor 
KIT aberrations, such as melanomas arising on skin with CSD. However, patients with 
mucosal/acral melanoma may be most appropriate for KIT inhibitor treatment because 
KIT mutations are most commonly observed in these subtypes [2].  
 
Overall, nilotinib demonstrated activity in patients with advanced melanoma with KIT 
mutations without prior KIT inhibitor treatment. Although these data did not show an 
advantage for nilotinib relative to historical data with imatinib, they do suggest that 
nilotinib may be an additional treatment option for patients with KIT-mutated advanced 
melanoma, for example, in patients intolerant of imatinib. The treatment landscape for 
advanced melanoma is rapidly changing with the availability of immunotherapies such 
as inhibitors of programmed cell death protein 1 (eg, nivolumab, pembrolizumab) or 
cytotoxic T lymphocyte–associated protein 4 (eg, ipilimumab), which have shown 
activity in acral and/or mucosal melanomas (ORRs, 11.4%-23.3%) [22-24]. Thus, a 
potential role for KIT inhibitors may be in combination with or following disease 
progression on immunotherapy. Further studies are needed to investigate the potential 
efficacy of nilotinib in patients with advanced KIT-mutated melanoma, either in 
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combination with immunotherapy or in the setting of disease refractory to 
immunotherapy. 
 
Acknowledgments 
The authors thank Steven Green (Novartis) for statistical input and Joy Loh, PhD, and 
Jonathan Morgan, PhD (ArticulateScience LLC), for medical editorial assistance with 
this manuscript. Financial support for medical editorial assistance was provided by 
Novartis Pharmaceuticals Corporation. 
 
Funding 
This study was supported by Novartis Pharmaceuticals Corporation. No grant number 
applied. 
 
Disclosures 
The authors declare the following relationships: JG: Bayer (consulting or advisory role), 
Novartis (consulting or advisory role), Merck (consulting or advisory role); RDC: 
Novartis (consulting or advisory role, research funding), AstraZeneca (consulting or 
advisory role, research funding), Merck (consulting or advisory role, research funding), 
Janssen (consulting or advisory role), Aura Biosciences (consulting or advisory role), 
Iconic Therapeutics (consulting or advisory role), Bristol-Myers Squibb (research 
funding), Eli Lilly (research funding), Daiichi-Sankyo (research funding), Amgen 
(research funding), Immunocore (research funding), Incyte (research funding), Celldex 
(research funding), Genentech (research funding), Mirati (research funding), 
16 
 
Macrogenics (research funding), Regeneron (research funding); RD: Novartis (research 
funding, consulting or advisory role), Merck Sharp & Dhome (research funding, 
consulting or advisory role), Bristol-Myers Squibb (research funding, consulting or 
advisory role), Roche (research funding, consulting or advisory role), GlaxoSmithKline 
(research funding, consulting or advisory role), Amgen (consulting or advisory role); AH: 
Amgen (consulting or advisory role, honoraria, research funding), Bristol-Myers Squibb 
(consulting or advisory role, honoraria, research funding), MedImmune (consulting or 
advisory role, honoraria), MSD/Merck (consulting or advisory role, honoraria, research 
funding), Nektar Therapeutics (consulting or advisory role, honoraria), Novartis 
(consulting or advisory role, honoraria, research funding), Oncosec (consulting or 
advisory role, honoraria), Philogen (consulting or advisory role, honoraria), Provectus 
(consulting or advisory role, honoraria), Regeneron (consulting or advisory role, 
honoraria), Roche (consulting or advisory role, honoraria, research funding), Celgene 
(research funding), Eisai (research funding), GlaxoSmithKline (research funding), Merck 
Serono (research funding); AD: OncoSec (stock or other ownership, patent or 
intellectual property), Novartis (consulting or advisory role), Merck (consulting or 
advisory role, research funding), Pfizer (consulting or advisory role, research funding), 
Genentech (consulting or advisory role, research funding), Bristol-Myers Squibb 
(research funding); BCB: Illumina (stock or other ownership), Novartis (stock or other 
ownership, consulting or advisory role), Roche (consulting or advisory role), Daiichi-
Sankyo (research funding), University of California (San Francisco) (institution holds a 
patent US 20140045182 A1); SM: No relationships to disclose; PQ: No relationships to 
disclose; AA: Novartis (research funding); CB: AstraZeneca (personal fees), Amgen 
17 
 
(personal fees), Bristol-Myers Squibb (personal fees, non-financial support), 
GlaxoSmithKline (personal fees), MSD (personal fees, non-financial support), Novartis 
(personal fees), Roche (personal fees, non-financial support), Pierre Fabre (personal 
fees); VC: No relationships to disclose; DH: No relationships to disclose; TP: Novartis 
(consulting or advisory role, honoraria, research funding); DS: Amgen (personal fees), 
GlaxoSmithKline (personal fees), Bristol-Myers Squibb (personal fees), Novartis 
(personal fees), Roche (personal fees), Merck (personal fees); WS: Bristol-Myers 
Squibb (grant, personal fees for consulting), Merck (grant, personal fees for consulting), 
Castle Biosciences (personal fees for consulting); AT: No relationships to disclose; SN: 
Novartis (employment and stock ownership); SH: Novartis (employment and stock 
ownership); CN: Novartis (employment and stock ownership); QC: Novartis 
(employment and stock ownership); FSH: Novartis (consulting or advisory role), Merck 
(consulting or advisory role), Genentech (consulting or advisory role), Synta (consulting 
or advisory role), Celldex (consulting or advisory role), Bristol-Myers Squibb (research 
funding paid to institution).  
18 
 
References 
1. Lovly CM, Dahlman KB, Fohn LE et al. Routine multiplex mutational profiling of 
melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One 
2012; 7: e35309. 
2. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct 
subtypes of melanoma. J Clin Oncol 2006; 24: 4340-4346. 
3. Corless CL. Other KIT mutations in melanoma. 
https://www.mycancergenome.org/content/disease/melanoma/kit/132/. Published 
October 22, 2014. Accessed September 9, 2016. 
4. Hodi FS, Friedlander P, Corless CL et al. Major response to imatinib mesylate in KIT-
mutated melanoma. J Clin Oncol 2008; 26: 2046-2051. 
5. Satzger I, Kuttler U, Volker B et al. Anal mucosal melanoma with KIT-activating 
mutation and response to imatinib therapy—case report and review of the literature. 
Dermatology 2010; 220: 77-81. 
6. Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a 
metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma 
Res 2008; 21: 492-493. 
7. Carvajal RD, Antonescu CR, Wolchok JD et al. KIT as a therapeutic target in 
metastatic melanoma. JAMA 2011; 305: 2327-2334. 
8. Guo J, Si L, Kong Y et al. Phase II, open-label, single-arm trial of imatinib mesylate in 
patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin 
Oncol 2011; 29: 2904-2909. 
19 
 
9. Hodi FS, Corless CL, Giobbie-Hurder A et al. Imatinib for melanomas harboring 
mutationally activated or amplified KIT arising on mucosal, acral, and chronically 
sun-damaged skin. J Clin Oncol 2013; 31: 3182-3190. 
10. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in 
melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516. 
11. Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic 
melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 
2012; 380: 358-365. 
12. Weisberg E, Manley PW, Breitenstein W et al. Characterization of AMN107, a 
selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141. 
13. Guo T, Hajdu M, Agaram NP et al. Mechanisms of sunitinib resistance in 
gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro 
mutagenesis screen for drug resistance. Clin Cancer Res 2009; 15: 6862-6870. 
14. Saglio G, Kim DW, Issaragrisil S et al. Nilotinib versus imatinib for newly diagnosed 
chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-2259. 
15. Carvajal RD, Lawrence DP, Weber JS et al. Phase II study of nilotinib in melanoma 
harboring KIT alterations following progression to prior KIT inhibition. Clin Cancer 
Res 2015; 21: 2289-2296. 
16. Lee SJ, Kim TM, Kim YJ et al. Phase II trial of nilotinib in patients with metastatic 
malignant melanoma harboring KIT gene aberration: a multicenter trial of Korean 
Cancer Study Group (UN10-06). Oncologist 2015; 20: 1312-1319. 
20 
 
17. Lebbe C, Chevret S, Jouary T et al. Phase II multicentric uncontrolled national trial 
assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-
KIT mutation or amplification. J Clin Oncol (Meeting Abstracts) 2014; 32: 9032. 
18. Lesteven E, Battistella M, Jouary T et al. Phase II multicentric uncontrolled national 
trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with 
c-KIT mutation or amplification: results of the pharmacodynamic study. J Clin Oncol 
(Meeting Abstracts) 2015; 33: e20062. 
19. Long GV, Menzies AM, Nagrial AM et al. Prognostic and clinicopathologic 
associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29: 
1239-1246. 
20. Torres-Cabala CA, Wang WL, Trent J et al. Correlation between KIT expression and 
KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-
lentiginous/mucosal type. Mod Pathol 2009; 22: 1446-1456. 
21. Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial 
of the Dartmouth regimen versus dacarbazine in patients with metastatic 
melanoma. J Clin Oncol 1999; 17: 2745-2751. 
22. Johnson DB, Peng C, Abramson RG et al. Clinical activity of ipilimumab in acral 
melanoma: a retrospective review. Oncologist 2015; 20: 648-652. 
23. Del Vecchio M, Di Guardo L, Ascierto PA et al. Efficacy and safety of ipilimumab 3 
mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer 
2014; 50: 121-127. 
21 
 
24. Larkin J, D'Angelo S, Sosman JA et al. Efficacy and safety of nivolumab (NIVO) 
monotherapy in the treatment of advanced mucosal melanoma (MEL). Pigment Cell 
Melanoma Res 2015; 28: 789. 
  
22 
 
Figure Legend 
Figure 1. Tumor response and survival following nilotinib treatment. A) Best percentage 
change from baselinea and best overall response to nilotinib. B) Kaplan-Meier estimate 
of PFSb. C) Kaplan-Meier estimate of OS. 
OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, 
partial response; RECIST, Response Evaluation Criteria In Solid Tumors; SD, stable 
disease; UNK, unknown. 
a Best percentage change from baseline determined from the sum of the longest 
diameter. 
b Patients who discontinued due to disease progression without PD per RECIST were 
not considered to have had a PFS event. 
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Table 1. Demographics and baseline characteristics 
Demographic variables 
Nilotinib 400 mg twice 
daily 
(N=42) 
Age, median (range), years 65.5 (20-87) 
<65 years, n (%) 20 (47.6) 
≥65 years, n (%) 22 (52.4) 
Sex, n (%)  
Male 19 (45.2) 
Female 23 (54.8) 
Race, n (%)  
Caucasian 26 (61.9) 
Asian 10 (23.8) 
Other 6 (14.3) 
WHO performance status, n (%)  
0 30 (71.4) 
1 10 (23.8) 
2 2 (4.8) 
Melanoma type and primary site, n (%)  
Acral 20 (47.6) 
Sole 8 (19.0) 
Subungual (hand) 4 (9.5) 
Subungual (foot) 2 (4.8) 
2 
 
Othera 6 (14.3) 
Mucosal 20 (47.6) 
Female genital tract 9 (21.4) 
Anorectal 4 (9.5) 
Head and neck 1 (2.4) 
Otherb 6 (14.3) 
CSD  2 (4.8) 
Head and neck 2 (4.8) 
Lactate dehydrogenase, n (%)  
Within or below normal range 30 (71.4) 
Above normal range 10 (23.8) 
Missing 2 (4.8) 
Prior systemic anticancer therapies,c n (%)  
Any therapy 13 (31.0) 
Chemotherapy 9 (21.4) 
Immunotherapy 2 (4.8) 
Otherd 6 (14.3) 
KIT mutation status, n (%)  
Exon 11 26 (61.9) 
L576P 10 (23.8)e 
V559A 3 (7.1) 
V560D 3 (7.1) 
W557C 2 (4.8) 
3 
 
W557R 2 (4.8) 
Otherf 6 (14.3) 
Exon 13 13 (31.0) 
K642E 10 (23.8) 
Otherg 3 (7.1) 
Exon 9h 2 (4.8) 
Exon 17 (Y823D) 1 (2.4) 
Time since initial diagnosis, median (range), months 13.2 (1.6-305.4) 
Time since most recent recurrence/relapse, median 
(range), days 
61 (1-761) 
CSD, chronic sun damage; WHO, World Health Organization. 
a Includes toe (n=4), heel (n=1), and thumb (n=1). 
b Includes esophagus (n=3), nasal mucosa (n=2), and intranasal (n=1). 
c Other than therapies received only in the adjuvant setting. 
d Includes recombinant human endostatin injection (n=4), bleomycin (n=1), and 
sargramostim (n=1). 
e Includes 1 patient with a combined L576P/W557R mutation. 
f Other mutations detected were D572G, K558E, K581_P585dup, V559D, V569I, and 
W557hetdel (n=1 each). 
g Other mutations detected were K642Q, R634W, and V654A (n=1 each). 
h Specific mutations were D496N and S476C (n=1 each). 
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Table 2. Response to nilotinib, overall and by KIT mutation status 
 Nilotinib 400 mg twice daily 
 
Total 
(N=42) 
Exon 11 
(n=26) 
Exon 13 
(n=13) 
Othera 
(n=3) 
Best overall response, n (%)b     
CR 0 0 0 0 
PR 11 (26.2) 10 (38.5) 1 (7.7) 0 
SD 20 (47.6) 13 (50.0) 5 (38.5) 2 (66.7) 
PD 10 (23.8) 3 (11.5) 6 (46.2) 1 (33.3) 
Unknown 1 (2.4)c 0 1 (7.7) 0 
ORR, % (95% CI)d 26.2 (13.9-42.0) 38.5 (12.1-39.5) 7.7 (0.1-12.6) 0 (0.0-8.4) 
DOR, median (95% CI), 
monthse 
7.1 (4.2-not 
defined) 
– – – 
DCR, % (95% CI)f 47.6 (32.0-63.6) 61.5 (23.6-54.4) 30.8 (2.7-22.6) 0 (0.0-8.4) 
PFS, median (95% CI), 
months 
4.2 (2.1-5.8) 5.4 (2.7-8.3) 2.8 (1.3-8.6) 2.1 (1.9-2.8) 
OS, median (95% CI), 
months 
18.0 (10.9-20.3) – – – 
CR, complete response; DCR, disease control rate; DOR, duration of objective 
response; ORR, objective response rate; OS, overall survival; PD, progressive disease; 
PFS, progression-free survival; PR, partial response; SD, stable disease. 
a Exon 9 and exon 17 (Y823D). 
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b Percentages for each mutation subgroup are reported according to the number of 
patients in the respective mutational subgroups. 
c This patient discontinued nilotinib on study day 11 and withdrew consent on study day 
22. 
d Rate of patients with CR + PR. 
e Median DOR was determined among the 11 responding patients. Median DOR was 
not determined according to mutation subgroups; however, all responding patients had 
an exon 11 mutation except for 1 patient with a mutation on exon 13 (DOR, 4.2 
months). 
f Rate of patients with CR + PR + SD >12 weeks. SD in DCR is defined as lasting ≥12 
week. 
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Table 3. Best overall response by KIT mutation 
Patient 
Melanoma 
type 
Exon KIT mutation 
Baseline 
tumor size, 
cm 
Best overall 
response 
PFS, 
months 
OS, 
months 
1 Acral 11 L576P 7.6 PR 24.9a 25.8b 
2 Mucosal 11 L576P 7.6 PR 5.4 9.4c 
3 Mucosal 11 L576P 22.1 PR 4.1 21.0b 
4 Acral 11 L576P 5.9 SD 2.1 6.6c 
5 Mucosal 11 L576P 3.8 SD 2.8a 16.4c 
6 Mucosal 11 L576P 12.3 SD 19.4 20.3c 
7 Mucosal 11 L576P 3.3 SD 4.2 18.0c 
8 Mucosal 11 L576P 28.1 SD 5.6 7.8c 
9 Mucosal 11 L576P 2.2 PD 1.5 2.3c 
10 CSD 11 V559A 2.0 PR 19.4 32.9b 
11 Mucosal 11 V559A 2.1 SD 2.3a 18.5d 
12 Acral 11 V559A 3.0 PD 0.7 1.0b 
50
51
52
53
54
55
56
57
58
59
60
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13 Acral 11 V560D 7.7 PR 8.6 23.5c 
14 Acral 11 V560D 2.2 SD 8.2 14.7c 
15 Acral 11 V560D 4.5 SD 2.7 6.0c 
16 Acral 11 W557C 5.4 SD 2.1 18.5c 
17 Acral 11 W557C 20.9 PD 0.7 1.4c 
18 Acral 11 W557R 3.8 PR 35.4a 35.4b 
19 Acral 11 W557R 5.6 SD 8.3 19.4b 
20 Acral 11 D572G 1.0 SD 2.1 14.9b 
21 Acral 11 K558E 9.2 SD 2.0 4.8e 
22 Acral 11 K581_P585dup 3.0 PR 8.3 16.5c 
23 Mucosal 11 L576P, W557R 9.2 PR 5.3 14.7b 
24 Acral 11 V559D 6.9 PR 28.3a 28.3b 
25 Mucosal 11 V569I 25.9 SD 5.3 5.3c 
26 Mucosal 11 W557hetdel 10.5 PR 8.0 18.0c 
27 Mucosal 13 K642E 1.2 PR 5.8 18.6c 
28 Acral 13 K642E 5.2 SD 11.0 17.0b 
50
51
52
53
54
55
56
57
58
59
60
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29 Mucosal 13 K642E 25.6 SD 2.8 5.5b 
30 Acral 13 K642E 10.1 SD 22.2a 22.9b 
31 Acral 13 K642E 5.6 SD 8.6 11.6c 
32 Mucosal 13 K642E 3.1 PD 1.5 17.8b 
33 Mucosal 13 K642E 3.9 PD 0.7 15.9c 
34 Acral 13 K642E 9.8 PD 1.4 6.4c 
35 Mucosal 13 K642E 9.0 PD 1.3 10.9c 
36 Mucosal 13 K642E 16.3 UNK 0.7a 0.7b 
37 CSD 13 K642Q 4.4 PD 1.4 27.9b 
38 Acral 13 R634W 12.4 PD 0.7 1.9c 
39 Acral 13 V654A 5.2 SD 2.9 24.8c 
40 Mucosal 9 D496N 1.8 PD 1.9 5.5c 
41 Mucosal 9 S476C 17.9 SD 2.8 4.0b 
42 Mucosal 17 Y823D 1.2 SD 2.1 9.7c 
CSD, chronic sun damage; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial 
response; SD, stable disease; UNK, unknown. 
49
50
51
52
53
54
55
56
57
58
59
60
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a
 Study day of censoring for PFS analysis. Patients were censored at the date of the last adequate tumor assessment (if 
they were alive and progression-free) or the first date of initiating other anticancer therapy. 
b
 Study day of censoring for OS analysis. If death was not observed, patients were censored at day of last contact. 
c
 Death due to study indication. 
d
 Death due to multi-organ dysfunction. 
e
 Death due to cardiopulmonary arrest. 
49
50
51
52
53
54
55
56
57
58
59
60
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Table 1. Demographics and baseline characteristics 
Demographic variables 
Nilotinib 400 mg twice 
daily 
(N=42) 
Age, median (range), years 65.5 (20-87) 
<65 years, n (%) 20 (47.6) 
≥65 years, n (%) 22 (52.4) 
Sex, n (%)  
Male 19 (45.2) 
Female 23 (54.8) 
Race, n (%)  
Caucasian 26 (61.9) 
Asian 10 (23.8) 
Other 6 (14.3) 
WHO performance status, n (%)  
0 30 (71.4) 
1 10 (23.8) 
2 2 (4.8) 
Melanoma type and primary site, n (%)  
Acral 20 (47.6) 
Sole 8 (19.0) 
Subungual (hand) 4 (9.5) 
Subungual (foot) 2 (4.8) 
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Othera 6 (14.3) 
Mucosal 20 (47.6) 
Female genital tract 9 (21.4) 
Anorectal 4 (9.5) 
Head and neck 1 (2.4) 
Otherb 6 (14.3) 
CSD  2 (4.8) 
Head and neck 2 (4.8) 
Lactate dehydrogenase, n (%)  
Within or below normal range 30 (71.4) 
Above normal range 10 (23.8) 
Missing 2 (4.8) 
Prior systemic anticancer therapies,c n (%)  
Any therapy 13 (31.0) 
Chemotherapy 8 (19.0)9 (21.4) 
Immunotherapy 2 (4.8) 
Otherd 6 (14.3) 
KIT mutation status, n (%)  
Exon 11 26 (61.9) 
L576P 10 (23.8)e 
V559A 3 (7.1) 
V560D 3 (7.1) 
W557C 2 (4.8) 
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W557R 2 (4.8) 
Otherf 6 (14.3) 
Exon 13 13 (31.0) 
K642E 10 (23.8) 
Otherg 3 (7.1) 
Exon 9h 2 (4.8) 
Exon 17 (Y823D) 1 (2.4) 
Time since initial diagnosis, median (range), months 13.2 (1.6-305.4) 
Time since most recent recurrence/relapse, median 
(range), days 
61 (1-761) 
CSD, chronic sun damage; WHO, World Health Organization. 
a Includes toe (n=4), heel (n=1), and thumb (n=1). 
b Includes esophagus (n=3), nasal mucosa (n=2), and intranasal (n=1). 
c Other than therapies received only in the adjuvant setting. 
d Includes recombinant human endostatin injection (n=4), bleomycin (n=1), and 
sargramostim (n=1). 
e Includes 1 patient with a combined L576P/W557R mutation. 
f Other mutations detected were D572G, K558E, K581_P585dup, V559D, V569I, and 
W557hetdel (n=1 each). 
g Other mutations detected were K642Q, R634W, and V654A (n=1 each). 
h Specific mutations were D496N and S476C (n=1 each). 
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Supplementary Appendix 
Supplement to Guo J, Carvajal RD, Dummer R, et al. Efficacy and Safety of Nilotinib in 
Patients With KIT-Mutated Metastatic or Inoperable Melanoma: Final Results From the 
Global, Single-Arm, Phase II TEAM Trial  
 2 
 
Supplementary Methods 
Dose Adjustments 
Dose adjustments (including interruption/reduction to nilotinib 400 mg once daily) were 
permitted for patients unable to tolerate the study dose per protocol-specified criteria. 
Dose interruption was recommended for patients with grade 3/4 hematologic or grade 
≥ 2 nonhematologic adverse events. If these returned to grade 1, nilotinib could be 
reinitiated at 400 mg once daily. Re-escalation to 400 mg twice daily was allowed 
following resolution and/or management with supportive therapy for ≥ 1 month, except 
for patients with dose reductions due to QTc prolongation. 
 
Study Endpoints and Assessments 
Progression-free survival (PFS) was defined as the time from treatment start to the date 
of first documented progression or death. PFS time was censored for any patient alive 
and progression free at study end or when the patient received a new anticancer 
therapy. The date of censoring was the date of the last adequate tumor assessment 
prior to the end of study or the initiation of another anticancer therapy, whichever was 
earlier. Patients were not considered to have experienced a PFS event if they 
discontinued due to disease progression according to the investigator without 
documented progressive disease per Response Evaluation Criteria In Solid Tumors 
(RECIST) during tumor assessment. Overall survival was defined as the time from study 
start to the date of death from any cause. Surviving patients were censored at the latest 
date they were known to be alive.  
 3 
 
Figure Legends 
Figure S1. Screening, enrollment, and patient disposition 
AE, adverse event; DTIC, dacarbazine. 
a Patient discontinued treatment early due to non-compliance with study treatment. 
b Patient discontinued treatment early because he/she was not followed with spiral 
computed tomography, as requested by the protocol. 
c As of 31 Dec 2014, 4 patients enrolled in the nilotinib arm (median follow-up, 26.6 
months) and 1 patient enrolled in the DTIC arm who crossed over to nilotinib treatment 
on study (duration of nilotinib treatment, 6.9 months) remained on nilotinib 400 mg twice 
daily after study completion through a rollover study or local protocol. 
d Due to the amendment of the TEAM trial to a phase II, single-arm study of nilotinib 
efficacy and safety, no statistical comparisons were made between the nilotinib and 
DTIC study arms. 
 
Figure S2. Kaplan-Meier estimates of (A) PFSa and (B) OS in the nilotinib and DTIC 
arms 
DTIC, dacarbazine; OS, overall survival; PFS, progression-free survival; RECIST, Response 
Evaluation Criteria In Solid Tumors. 
a Patients who discontinued due to disease progression without progressive disease per 
RECIST were not considered to have had a PFS event. 
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Table S1. Comparison of the effects of imatinib and nilotinib on wild-type and mutant 
KIT autophosphorylation and proliferation in cells 
KIT mutant 
(cell type) 
Mean IC50 value, nM 
Imatinib Nilotinib 
Autophos-
phorylation Proliferation 
Autophos-
phorylation Proliferation 
Wild-type KIT 
(Ba/F3) [1] 
ND 3132 ND 35 
A502_Y503dup 
(Ba/F3)a 
775 376 618 205 
A502_Y503dup 
(Ba/F3) [2] 
ND 509 ND 671 
W557_K558del 
(Ba/F3) [2] 
ND 460 ND 83 
W557_K558delT6
70I (Ba/F3) [2] 
ND > 10,000 ND > 10,000 
V559D (Ba/F3) [1] ND 63 ND 44 
V559_V560del 
(Ba/F3)a 
45 25 31 23 
V559D/D820Y 
(Ba/F3) [2] 
ND 3202 ND 297 
V560delV654A 
(Ba/F3) [2] 
ND 3927 ND 192 
L576P (Ba/F3) [3] ND 253 ND 185 
R634W (Ba/F3)a 813 396 384 255 
K642E (GIST882)a 96 120 210 158 
T670I (Ba/F3) [2] ND > 10,000 ND > 10,000 
D816V (Ba/F3)a > 10,000 > 10,000 5280 4570b 
D816Y (Ba/F3)a 2400 3249 737 744 
N822K (Ba/F3) [2] ND > 10,000 ND 3083 
(Parental Ba/F3 + 
IL-3)a 
NA 7384 NA > 10,000 
IC50, half-maximal inhibitory concentration; NA, not applicable; ND, not determined 
a Source: data on file. 
b 4570 (n = 6) does not include 8 measures of > 10,000. 
 
Table S2. Best overall response in DTIC-treated patients 
Parameter 
DTIC 
(N = 13) 
Best overall response, n (%)a  
CR 0 
PR 3 (23.1) 
SD 6 (46.2) 
PD 4 (30.8) 
ORR (95% CI), %b 23.1 (5.0 to 53.8) 
Median DOR (95% CI), monthsc 3.7 (2.8 to 12.7) 
DCR (95% CI), %d 53.8 (25.1 to 80.8) 
Median PFS (95% CI), monthse 4.2 (0.8 to 8.0) 
Median OS (95% CI), monthsf 22.8 (4.9 to not defined) 
CR, complete response; DCR, disease control rate; DOR, duration of objective 
response; DTIC, dacarbazine; ORR, overall response rate; OS, overall survival; PD, 
progressive disease; PFS, progression-free survival; PR, partial response; SD, stable 
disease. 
a Responses following crossover to nilotinib are not included. One additional patient 
achieved PR following switch to nilotinib. 
b Rate of patients with CR + PR. 
c Median DOR was determined among the 3 responding patients. 
d Rate of patients with CR + PR + SD > 12 weeks. SD in DCR is defined as lasting ≥ 12 
weeks. 
e PFS was censored at the time of crossover to nilotinib treatment. 
f OS analysis includes data obtained after crossover for the 10 patients who crossed 
over. 
 
Table S3. Response by specific mutation in DTIC-treated patients 
Patient 
Melanoma 
type 
Exon 
KIT 
mutation 
Baseline 
tumor size, 
cm 
Best overall 
response 
PFS, 
months 
OS, 
months 
1 Acral 11 L576P 11.6 PR 4.4 29.2a 
2b CSD 11 L576P 18.5 PR 14.1 23.9c 
3b Mucosal 11 L576P 22.6 PD 0.8 4.9d 
4b Mucosal 11 L576P 5.6 PD 1.2 7.8d 
5b Acral 11 V559A 2.2 PR 4.2 9.7d 
6 Other 11 V559A 1 SD 2.7e 26.6a 
7b Acral 13 K642E 1.9 SD 1.6e 24.4a 
8b Mucosal 13 K642E 3.8 SD 5.5 13.1d 
9b Acral 13 K642E 1.3 SD 3.5 31.5d 
10b Mucosal 13 K642E 18 SD 8.0 21.7d 
11 Acral 13 K642E 11.3 PD 0.7 0.9a 
12b Mucosal 17 Y823D 9.4 PD 0.7 3.1d 
13b Acral 9/11 
A493V/ 
N567_T574
delinsKE 
8.4 SD 2.1e 39.4a 
CSD, chronic sun damage; DTIC, dacarbazine; OS, overall survival; PD, progressive 
disease; PFS, progression-free survival; PR, partial response; SD, stable disease. 
a Study day of censoring for OS analysis. If death was not observed, patients were 
censored on day of last contact. 
b Patient crossed over to nilotinib treatment on study. 
c Death due to infection. 
d Death due to study indication. 
e Study day of censoring for PFS analysis. Patients were censored at the date of the 
last adequate tumor assessment (if they were alive and progression free) or the first 
date of initiating other anticancer therapy (including crossover to nilotinib treatment). 
Table S4. Most frequently reported all-cause adverse events (≥ 5%) in the nilotinib arm 
 
Nilotinib 400 mg twice daily 
(N = 42) 
Patients, n (%) All grades Grade 3/4 
Total 41 (97.6) 25 (59.5) 
Rash 20 (47.6) 1 (2.4) 
Blood bilirubin increased 19 (45.2) 3 (7.1) 
Nausea 18 (42.9) 2 (4.8) 
Decreased appetite 13 (31.0) 0 
Fatigue 13 (31.0) 0 
Vomiting 12 (28.6) 2 (4.8) 
Conjugated bilirubin increased 11 (26.2) 1 (2.4) 
γ-Glutamyltransferase increased 11 (26.2) 5 (11.9) 
ALT increased 10 (23.8) 2 (4.8) 
Amylase increased 9 (21.4) 5 (11.9) 
Unconjugated blood bilirubin 
increased 
9 (21.4) 0 
Constipation 9 (21.4) 0 
Cough 9 (21.4) 0 
Hyperglycemia 9 (21.4) 2 (4.8) 
AST increased 8 (19.0) 0 
Lipase increased 8 (19.0) 6 (14.3) 
Diarrhea 7 (16.7) 1 (2.4) 
Headache 6 (14.3) 0 
Hypokalemia 6 (14.3) 4 (9.5) 
Alopecia 5 (11.9) 0 
Anemia 5 (11.9) 0 
Blood alkaline phosphatase 
increased 
5 (11.9) 0 
Dyspnea 5 (11.9) 0 
Hypocalcemia 5 (11.9) 0 
Insomnia 5 (11.9) 0 
Pain in extremity 5 (11.9) 0 
Upper abdominal pain  4 (9.5) 1 (2.4) 
Arthralgia 4 (9.5) 0 
Blood lactate dehydrogenase 
increased 
4 (9.5) 0 
Blood pressure decreased 4 (9.5) 0 
Dizziness 4 (9.5) 0 
Hypercholesterolemia 4 (9.5) 0 
Abdominal distension 3 (7.1) 0 
Abdominal pain 3 (7.1) 1 (2.4) 
Asthenia 3 (7.1) 1 (2.4) 
Chills 3 (7.1) 0 
Dyspepsia 3 (7.1) 0 
Hyperkalemia 3 (7.1) 0 
Hypertension 3 (7.1) 0 
Hyperuricemia 3 (7.1) 0 
Leukopenia 3 (7.1) 1 (2.4) 
Lymphopenia 3 (7.1) 1 (2.4) 
Nasopharyngitis 3 (7.1) 0 
Peripheral edema  3 (7.1) 0 
Pruritus 3 (7.1) 0 
Pyrexia 3 (7.1) 1 (2.4) 
Urinary tract infection 3 (7.1) 0 
ALT, alanine aminotransferase; AST, aspartate aminotransferase. 
 
 
Table S5. All-cause serious adverse events and adverse events of interest in the 
nilotinib arm 
Patients, n (%) 
Nilotinib 400 mg twice daily 
(N = 42) 
Serious adverse events 12 (28.6) 
Nausea 3 (7.1) 
Vomiting 3 (7.1) 
Abdominal pain 2 (4.8) 
Lipase increased 2 (4.8) 
Upper abdominal pain  1 (2.4) 
Amylase increased 1 (2.4) 
Angina pectorisa 1 (2.4) 
Ankle fracture 1 (2.4) 
Asthenia 1 (2.4) 
Blood creatinine increased 1 (2.4) 
Dehydration 1 (2.4) 
Dizziness 1 (2.4) 
Fatigue 1 (2.4) 
Hematuria 1 (2.4) 
Joint dislocation 1 (2.4) 
Lower respiratory tract 
infections 
1 (2.4) 
Malaise 1 (2.4) 
CNS metastasis 1 (2.4) 
Pleural effusion 1 (2.4) 
Visual impairment 1 (2.4) 
Adverse events leading to 
discontinuation 
2 (4.8) 
Lipase increased 1 (2.4) 
Nausea 1 (2.4) 
Presyncope 1 (2.4) 
Vomiting 1 (2.4) 
CNS, central nervous system. 
a This patient had a history of cardiac dysfunction; experienced grade 2 angina pectoris 
not suspected to be related to nilotinib on study day 3, followed by grade 3 angina 
pectoris not suspected to be related to nilotinib on study day 6 requiring hospitalization; 
was discontinued due to protocol deviation on study day 49; and died 3 months later 
due to cardiopulmonary arrest. 
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Table S6. Any-grade, all-cause adverse events in DTIC-treated patients 
 
DTIC 
(N = 13) 
Patients, n (%) All grades Grade 3/4 
Total 9 (69.2) 2 (15.4) 
Fatigue 5 (38.5) – 
Headache 5 (38.5) – 
Nausea 5 (38.5) – 
Pyrexia 3 (23.1) – 
Cough 2 (15.4) – 
Decreased appetite 2 (15.4) – 
Dizziness 2 (15.4) – 
Muscle spasm 2 (15.4) – 
Nasopharyngitis 2 (15.4) – 
Pain in extremity 2 (15.4) – 
Rash 2 (15.4) – 
Alopecia 1 (7.7) – 
ALT increased 1 (7.7) – 
Anxiety 1 (7.7) – 
AST increased 1 (7.7) – 
Asthenia 1 (7.7) – 
Blood bilirubin increased 1 (7.7) – 
Blood cholesterol 
increased 
1 (7.7) – 
Blood pressure 
increased 
1 (7.7) – 
Constipation 1 (7.7) – 
Depression 1 (7.7) – 
Diarrhea 1 (7.7) – 
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Dry skin 1 (7.7) – 
Dyspepsia 1 (7.7) – 
Dyspnea 1 (7.7) – 
Ear infection 1 (7.7) – 
Peripheral edema  1 (7.7) – 
Erysipelas 1 (7.7) – 
Fall 1 (7.7) – 
Feeling cold 1 (7.7) – 
γ-Glutamyltransferase 
increased 
1 (7.7) – 
Gastrointestinal infection 1 (7.7) – 
Gingivitis 1 (7.7) – 
Hemangioma 1 (7.7) – 
Hypercholesterolemia 1 (7.7) – 
Hyperglycemia 1 (7.7) – 
Hypertriglyceridemia 1 (7.7) – 
Insomnia 1 (7.7) – 
Lipase increased 1 (7.7) – 
Lymphedema 1 (7.7) – 
Monoplegia 1 (7.7) – 
Myalgia 1 (7.7) – 
Nasal congestion 1 (7.7) – 
Neutropenia 1 (7.7) – 
Neutrophil count 
decreased 
1 (7.7) 1 (7.7) 
Night sweats 1 (7.7) – 
Odynophagia 1 (7.7) – 
Oral discomfort 1 (7.7) – 
Oral herpes 1 (7.7) – 
Otorrhea 1 (7.7) – 
Paresthesia 1 (7.7) – 
Photosensitivity reaction 1 (7.7) – 
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Platelet count decreased 1 (7.7) 1 (7.7) 
Pneumonia 1 (7.7) 1 (7.7) 
Pruritus 1 (7.7) – 
Skin burning sensation 1 (7.7) – 
Skin hypopigmentation 1 (7.7) – 
Throat irritation 1 (7.7) – 
Thrombocytopenia 1 (7.7) – 
Tumor pain 1 (7.7) – 
Vaginal hemorrhage 1 (7.7) – 
Vein disorder 1 (7.7) – 
Vomiting 1 (7.7) – 
Wheezing 1 (7.7) – 
Wound 1 (7.7) – 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; DTIC, dacarbazine. 
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Table S7. Results from previous clinical trials of nilotinib or imatinib in patients with advanced KIT-mutated melanoma 
 
Population Treatment ORR, % 
DOR, median 
(range), 
weeks 
PFS/TTP, 
median (95% 
CI), months 
OS, median 
(95% CI), 
months 
Lee et al, 
2015 [4] 
Pts with KIT aberrations 
without prior KIT 
inhibitors (N = 42) 
Nilotinib 
16.7 
Mutations: 
22.2a 
Amplifications: 
6.7 
34 (5-55) 3.3 (1.6-4.9) 11.9 (7.1-16.7) 
Lebbe et 
al, 2014 [5] 
Pts with KIT aberrations 
without prior KIT 
inhibitors (N = 25) 
Nilotinib 20b ND ND ND 
Carvajal et 
al, 2015 [6] 
Pts with KIT mutations 
with prior KIT-inhibitor 
resistance (N = 20) 
Nilotinib 18.2c ND 3.4 (0.9-5.5)c,d 14.2 (7.1-NE)c,d 
Carvajal et 
al, 2011 [7] 
Pts with KIT aberrations 
(N = 28) 
Imatinib 21.4e ND (12-95) 2.8 (2.5-4.0) 10.7 (6.5-NE) 
Guo et al, 
2011 [8] 
Pts with KIT aberrations 
(N = 43) 
Imatinib 23.3f ND 3.5 14.0 
Hodi et al, 
2013 [9] 
Pts with KIT aberrations 
(N = 24 evaluable pts) 
Imatinib 29.2g ND 3.7 (2.6-5.6) 12.5 (8.8-18.0) 
DOR, duration of response; ND, not determined; NE, not estimable; ORR, objective response rate; OS, overall survival; 
PFS, progression-free survival; Pt, patient; TTP, time to progression. 
a Of the 6 responding pts with KIT mutations, 5 had exon 11 mutations, including 3 with L576P. 
b All responding pts had KIT mutations; exon 11 and 13 mutations were associated with response to nilotinib [10]. 
c Determined among the 11 pts without brain metastases. 
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d In Carvajal et al, 2015, TTP and OS were reported with 90% CI. 
e All responding pts had L576P (exon 11) or K642E (exon 13) mutations. 
f Nine of 10 responding patients had mutations in exon 11 or 13. 
g All 7 responding patients had KIT mutations, of which 5 were in exon 11 (L576P; n = 3). 
50
51
52
53
54
55
56
57
58
59
60
106 Confirmed KIT 
mutation
55 Enrolled
877 Prescreened
42 Assigned to nilotinib 400 mg 
twice daily
13 Assigned to DTIC
13 Patients  analyzedd
• 0 Patients excluded from efficacy analyses
• 0 Patients excluded from safety analyses
3 Discontinued treatment early
1 Administrative problemsb
1 Disease progression
1 Lost to follow-up
4 Nilotinib treatment ongoing
c
42 Patients   analyzedd
• 0 Patients excluded from 
efficacy analyses
• 0 Patients excluded from 
safety analyses
38 Discontinued treatment early
33 Disease progression
2 AE(s)
1 Administrative problemsa
1 Protocol deviation
1 Withdrew consent
10 Crossed over to nilotinib   
400 mg twice daily
8 Disease progression 
2 No disease progression 
prior to crossover
9 Discontinued treatment early 
after crossover
8 Disease progression
1 Death
1 Nilotinib treatment ongoing
c
3 Remained on DTIC 
throughout  the study
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